600488.SH
津药药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.17
−6.17%Year over year
Reported trailing growth
- Revenue
- -13.0%
- EBITDA
- —
- EBIT
- -41.7%
- EPS
- -79.9%
- Free cash flow
- -81.0%
- Operating cash flow
- -73.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.6%
- EBITDA
- +14.0%
- EBIT
- +39.3%
- Net income
- +25.8%
- EPS
- +26.6%
- Free cash flow
- -43.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026